Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer
Diagnostics · 26.09.2024 · 14 (19) · 2137
DOI: 10.3390/diagnostics14192137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 26.09.2024. Verfasst von Melinda Lillesand und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Western Norway Regional Health Authority, Folke Hermansen Foundation.
Abstract (Originalsprache)
Background
Urothelial carcinoma presents as non-muscle-invasive bladder cancer (NMIBC) in ~75% of primary cases. Addressing the limitations of the TNM and WHO04/16 classification systems, this study investigates genetic alterations, the mitotic activity index (MAI), and immunohistochemistry (IHC) markers CK20, p53, and CD25 as better prognostic biomarkers in NMIBC.
Methods
Using the Oncomine™ Focus Assay for targeted next-generation sequencing (NGS), 409 single-nucleotide variations (SNVs) and 193 copy number variations (CNVs) were identified across 287 patients with TaT1 tumors.
Results
FGFR3 and PIK3CA alterations were significantly more prevalent in Ta tumors, while T1 tumors had significant ERBB2 alterations. Low-grade (LG) tumors were enriched with FGFR3 alterations, while high-grade (HG) tumors were significantly associated with ERBB2 alterations, as well as FGFR1 and CCND1 amplifications. FGFR3 alterations were linked to shorter recurrence-free survival (RFS; p = 0.033) but improved progression-free survival (PFS; p < 0.001). Conversely, ERBB2 alterations (p < 0.001), ERBB3 mutations (p = 0.044), and both MYC (p < 0.001) and MYCN (p = 0.011) amplifications were associated with shorter PFS. Survival analysis of gene sets revealed inverse associations between PIK3CA and ERBB2 (p = 0.003), as well as PIK3CA and MYC (p = 0.005), with PFS.
Conclusions
In multivariate Cox regression, MAI was the strongest predictor for PFS. Integrating genetic alterations and histopathological features may improve risk stratification in NMIBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway.
- Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway.
- Department of Forensic Medicine, Oslo University Hospital, 0372 Oslo, Norway.
- Department of Research, Section for Biostatistics, Stavanger University Hospital, 4011 Stavanger, Norway.
ORCID-Profile: Emiel A M Janssen
Förderung
- Western Norway Regional Health Authority
- Folke Hermansen Foundation
Zitieren
APA
Lillesand, M., Kvikstad, V., Gudlaugsson, E., Skaland, I., Slewa Johannessen, A., Nigatu Tesfahun, A., Sperstad, S. V., Janssen, E. A. M., & Austdal, M. (2024). Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer. Diagnostics, 14(19), 2137. https://doi.org/10.3390/diagnostics14192137
Vancouver
Lillesand M, Kvikstad V, Gudlaugsson E, Skaland I, Slewa Johannessen A, Nigatu Tesfahun A, et al. Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer. Diagnostics. 2024;14(19):2137. doi:10.3390/diagnostics14192137
BibTeX
@article{Lillesand2024,
author = {Lillesand, Melinda and Kvikstad, Vebjørn and Gudlaugsson, Einar and Skaland, Ivar and Slewa Johannessen, Aida and Nigatu Tesfahun, Almaz and Sperstad, Sigmund Vegard and Janssen, Emiel A M and Austdal, Marie},
title = {Integrating Genetic Alterations and Histopathological Features for Enhanced Risk Stratification in Non-Muscle-Invasive Bladder Cancer},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {19},
pages = {2137},
doi = {10.3390/diagnostics14192137}
}
EUVIMED